
Advocacy groups are pressing U.S. federal regulators to fast-track approval of an experimental drug treatment for the deadly neurological disease ALS (amyotrophic lateral sclerosis), with a decision expected this week. The push to approve the drug, so far just called AMX0035, is based on partial data from clinical trials and follows the U.S. Food and… read on > read on >